Karyopharm Extends Forbearance Period to October 22 as Debt Crisis Continues
KPTI is trading near its 52-week low of $0.396 (8.6% above the low).
Summary
Karyopharm extended its forbearance agreement with creditors by one week, from October 15 to October 22, 2026, as it continues to negotiate a resolution to its debt default.
Key Events · Legal and Risk Events · KPTI
-
Forbearance Extended One Week
The forbearance period under the September 10, 2026 agreement was extended from October 15 to October 22, 2026, giving the company seven additional days to negotiate with creditors.
-
Debt Default Unresolved
The extension follows Karyopharm's missed $15.8 million debt payment in September 2026 and its prior warning that it may not survive as a going concern.
-
Cash Runway Exhausted
As of the last 10-Q filed August 13, 2026, the company had cash only into September 2026, meaning it is now operating without a stated cash runway.
-
Next Milestone: October 22
The forbearance period now ends at 11:59 p.m. Eastern time on October 22, 2026, unless further extended or terminated earlier.
Analysis · KPTI · Life Sciences
Creditors have granted Karyopharm a one-week extension of the forbearance period, moving the deadline from October 15 to October 22, 2026. This is a short-term reprieve, not a resolution. The company missed a $15.8 million debt payment in September and has warned it may not survive. The extension gives management seven more days to negotiate a restructuring or secure financing, but the underlying distress is unchanged. With cash runway already exhausted as of September and substantial doubt about its ability to continue as a going concern, this filing confirms the company remains in active default negotiations.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 29.1% of the 1502 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPTI was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.40 to $10.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.